Monitor for future clinical development of these patented combinations, partnerships with larger biotech firms, or licensing activity. The lack of clinical validation means any value remains speculative at this stage.
Price Chart
Executive Summary
Clearmind Medicine announced the publication of six patents in Hong Kong covering proprietary combination therapies that pair palmitoylethanolamide (PEA) with psychedelic compounds like MDMA, LSD, ketamine, ibogaine, psilocybin, and DMT. The patents aim to enhance therapeutic efficacy and safety profiles for mental health treatments, expanding the company's global IP portfolio. However, no clinical data, revenue impact, or commercial timelines were disclosed.
Key Facts
- Six patents published in Hong Kong covering PEA-based combination therapies with major psychedelics (MDMA, LSD, ketamine, ibogaine, psilocybin, DMT).
- Patents focus on synergistic formulations to improve neuroplasticity, safety, and tolerability.
- PEA is sourced through a partnership with NeuroThera Labs Inc. (TSXV: NTLX).
- Clearmind's IP portfolio now includes 19 patent families and 31 granted patents.
- No clinical trial results, revenue figures, or commercialization timelines were provided.
Financial Impact
No immediate financial impact; potential long-term value if patents lead to protectable drug candidates.
Risk Factors
- Patent publications do not guarantee issued claims or enforceability.
- No clinical data supports the efficacy or safety of these combinations.
- High regulatory and development risk given the early-stage, pre-clinical nature of the IP.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257304 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.75%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.41%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.27%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers